
Vincent Huin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1533701/publications.pdf Version: 2024-02-01



VINCENT HUIN

#	Article	IF	CITATIONS
1	Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies. Molecular Therapy, 2022, 30, 782-797.	3.7	17
2	Clinical and genetic spectra of 1550 index patients with hereditary spastic paraplegia. Brain, 2022, 145, 1029-1037.	3.7	27
3	Cramp-fasciculation syndrome phenotype of cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS) due to RFC1 repeat expansion. Clinical Neurophysiology, 2022, 134, 34-36.	0.7	2
4	Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer's disease pathology in a mouse model. Progress in Neurobiology, 2022, 209, 102212.	2.8	15
5	A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics. Acta Neuropathologica Communications, 2022, 10, 20.	2.4	5
6	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
7	Motor neuron pathology in CANVAS due to <i>RFC1</i> expansions. Brain, 2022, 145, 2121-2132.	3.7	32
8	Brain Peri-Hematomal Area, a Strategic Interface for Blood Clearance: A Human Neuropathological and Transcriptomic Study. Stroke, 2022, 53, 2026-2035.	1.0	10
9	Functional Analyses of Two Novel <scp><i>LRRK2</i></scp> Pathogenic Variants in Familial Parkinson′s Disease. Movement Disorders, 2022, 37, 1761-1767.	2.2	5
10	Increasing involvement of CAPN1 variants in spastic ataxias and phenotype-genotype correlations. Neurogenetics, 2021, 22, 71-79.	0.7	11
11	Reply: Two heterozygous progranulin mutations in progressive supranuclear palsy. Brain, 2021, 144, e28-e28.	3.7	2
12	Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. Acta Neuropathologica Communications, 2021, 9, 112.	2.4	8
13	Neutrophil extracellular traps (NETs) infiltrate haematoma and surrounding brain tissue after intracerebral haemorrhage: A postâ€mortem study. Neuropathology and Applied Neurobiology, 2021, 47, 867-877.	1.8	16
14	P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy. Progress in Neurobiology, 2021, 206, 102139.	2.8	23
15	Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. Alzheimer's Research and Therapy, 2021, 13, 19.	3.0	25
16	Association of Amyotrophic Lateral Sclerosis and Alzheimer's Disease: New Entity or Coincidence? A Case Series. Journal of Alzheimer's Disease, 2021, 84, 1439-1446.	1.2	2
17	Reply: Early-onset phenotype of bi-allelic <i>GRN</i> mutations. Brain, 2021, 144, e23-e23.	3.7	0
18	Small vessel disease pathological changes in neurodegenerative and vascular dementias concomitant with autonomic dysfunction. Brain Pathology, 2020, 30, 191-202.	2.1	27

VINCENT HUIN

#	Article	IF	CITATIONS
19	Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. Brain, 2020, 143, 303-319.	3.7	54
20	Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. Neurobiology of Aging, 2020, 91, 167.e1-167.e9.	1.5	24
21	The TMEM240 Protein, Mutated in SCA21, Is Expressed in Purkinje Cells and Synaptic Terminals. Cerebellum, 2020, 19, 358-369.	1.4	5
22	Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations. Parkinsonism and Related Disorders, 2020, 80, 73-81.	1.1	13
23	Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain, 2019, 142, 3636-3654.	3.7	71
24	Neurogenetics of the Human Adenosine Receptor Genes: Genetic Structures and Involvement in Brain Diseases. Journal of Caffeine and Adenosine Research, 2019, 9, 73-88.	0.8	9
25	Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathologica Communications, 2018, 6, 132.	2.4	72
26	Expanding the phenotype of SCA19/22: Parkinsonism, cognitive impairment and epilepsy. Parkinsonism and Related Disorders, 2017, 45, 85-89.	1.1	25
27	Alternative promoter usage generates novel shorter MAPT mRNA transcripts in Alzheimer's disease and progressive supranuclear palsy brains. Scientific Reports, 2017, 7, 12589.	1.6	23
28	Clusterin/Apolipoprotein <scp>J</scp> immunoreactivity is associated with white matter damage in cerebral small vessel diseases. Neuropathology and Applied Neurobiology, 2016, 42, 194-209.	1.8	19
29	The <i>MAPT</i> gene is differentially methylated in the progressive supranuclear palsy brain. Movement Disorders, 2016, 31, 1883-1890.	2.2	25
30	Punctate pattern. Neurology, 2016, 86, 1516-1523.	1.5	65
31	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	2.6	333
32	Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics. Journal of Alzheimer's Disease, 2015, 49, 1075-1083.	1.2	3
33	A geographical cluster of progressive supranuclear palsy in northern France. Neurology, 2015, 85, 1293-1300.	1.5	53
34	TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. Brain, 2014, 137, 2657-2663.	3.7	52
35	Use of dried blood spots and inductively coupled plasma mass spectrometry for multi-element determination in blood. Journal of Trace Elements in Medicine and Biology, 2014, 28, 255-259.	1.5	20
36	MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1. Journal of Neurology, 2013, 260, 998-1003.	1.8	12

VINCENT HUIN

#	Article	IF	CITATIONS
37	C9ORF72 Repeat Expansions in the Frontotemporal Dementias Spectrum of Diseases: A Flow-chart for Genetic Testing. Journal of Alzheimer's Disease, 2013, 34, 485-499.	1.2	93
38	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
39	Development of a Nonfluorescent Multiplex Semiquantitative Polymerase Chain Reaction to Confirm Rearrangements Detected by Array-Comparative Genomic Hybridization. Genetic Testing and Molecular Biomarkers, 2011, 15, 469-474.	0.3	1
40	Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain, 2009, 132, 583-591.	3.7	344
41	Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiology of Disease, 2008, 31, 41-45.	2.1	66
42	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain, 2008, 131, 732-746.	3.7	331